Ikbkb Sirna-Encapsulated Poly (Lactic-Co-Glycolic Acid) Nanoparticles Diminish Neuropathic Pain By Inhibiting Microglial Activation

Activation of nuclear factor-kappa B (NF-kappa B) in microglia plays a decisive role in the progress of neuropathic pain, and the inhibitor of kappa B (I kappa B) is a protein that blocks the activation of NF-kappa B and is degraded by the inhibitor of NF-kappa B kinase subunit beta (IKBKB). The role of IKBKB is to break down I kappa B, which blocks the activity of NF-kB. Therefore, it prevents the activity of NK-kB. This study investigated whether neuropathic pain can be reduced in spinal nerve ligation (SNL) rats by reducing the activity of microglia by delivering IKBKB small interfering RNA (siRNA)-encapsulated poly (lactic-co-glycolic acid) (PLGA) nanoparticles. PLGA nanoparticles, as a carrier for the delivery of IKBKB genes silencer, were used because they have shown potential to enhance microglial targeting. SNL rats were injected with IKBKB siRNA-encapsulated PLGA nanoparticles intrathecally for behavioral tests on pain response. IKBKB siRNA was delivered for suppressing the expression of IKBKB. In rats injected with IKBKB siRNA-encapsulated PLGA nanoparticles, allodynia caused by mechanical stimulation was reduced, and the secretion of pro-inflammatory mediators due to NF-kappa B was reduced. Delivering IKBKB siRNA through PLGA nanoparticles can effectively control the inflammatory response and is worth studying as a treatment for neuropathic pain.